Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labiana HealthXMAD:LAB +1.59%56 EV-to-Revenue is 1.13 as of Aug. 14, 2026, which is 24% above its 10-year median of 0.91. GuruFocus rates XMAD:LAB with a GF Score™ of 56/100 and a GF Value™ of €3.61 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 963 Drug Manufacturers companies, Labiana Health ranks better than 76.22% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Labiana Health's enterprise value is €84.76 Mil.
Labiana Health's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €75.18 Mil. Therefore, Labiana Health's EV-to-Revenue for today is 1.13.
The historical rank and industry rank for Labiana Health's EV-to-Revenue or its related term are showing as below:
XMAD:LAB'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.73 Med: 0.91 Max: 1.33
Current: 1.12
During the past 6 years, the highest EV-to-Revenue of Labiana Health was 1.33. The lowest was 0.73. And the median was 0.91.
XMAD:LAB's EV-to-Revenue is ranked better than 76.22% of 963
companies
in the Drug Manufacturers industry
Industry Median: 2.49
vs XMAD:LAB: 1.12
As of today (2026-08-14), Labiana Health's stock price is €6.40.
Labiana Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €10.35. Therefore, Labiana Health's PS Ratio for today is 0.62.
Labiana Health's share price for today is €6.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2025 was €10.35.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labiana Health EV-to-Revenue Related Terms
Labiana Health EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for Labiana Health's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:LAB vs ZTS, UTHR, VTRS: EV-to-Revenue Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labiana Health EV-to-Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labiana Health's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Labiana Health's EV-to-Revenue falls into.
Labiana Health's current Enterprise Value is €84.76 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Labiana Health's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €75.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labiana Health (XMAD:LAB) has a EV-to-Revenue of 1.13 as of Aug. 14, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Labiana Health and its competitors. This is 24% above median its historical median of 0.91. Over the past decade, Labiana Health's EV-to-Revenue has ranged from 0.73 to 1.33. According to the industry distribution chart, Labiana Health ranks #229 out of 963 companies in the Drug Manufacturers industry, placing it in the top 23.8%.
Is Labiana Health's EV-to-Revenue too high?
Labiana Health's current EV-to-Revenue of 1.13 is 24% above median its 10-year median of 0.91. Over the past 10 years, this metric has ranged from a low of 0.73 to a high of 1.33. The Drug Manufacturers industry median EV-to-Revenue is 2.49. Labiana Health's value of 1.13 is 54.6% below this industry median. Based on the distribution chart, Labiana Health ranks #229 out of 963 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Labiana Health has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's EV-to-Revenue compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labiana Health ranks #229 out of 963 companies for EV-to-Revenue. This places Labiana Health in the top 24% of its industry — outperforming the majority of peers. The industry median EV-to-Revenue is 2.49. Labiana Health's value of 1.13 is 54.6% below this benchmark. Historically, Labiana Health's own EV-to-Revenue has ranged from 0.73 to 1.33 over the past decade. While the company's 10-year median is 0.91 vs. the industry median of 2.49, Labiana Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Drug Manufacturers company?
The median EV-to-Revenue among Drug Manufacturers companies is 2.49, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labiana Health's current EV-to-Revenue of 1.13 is 54.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Labiana Health and its competitors. For the Drug Manufacturers industry, the median EV-to-Revenue is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labiana Health's current EV-to-Revenue is 1.13, which is 24% above median its own 10-year median of 0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (XMAD:LAB) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.61, compared to a current price of €6.40 — trading 77.3% above its estimated fair value. The current EV-to-Revenue is 1.13, which is 24% above median its 10-year median of 0.91 and 54.6% below the Drug Manufacturers industry median of 2.49. Labiana Health's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For Labiana Health (XMAD:LAB), the current EV-to-Revenue is 1.13 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labiana Health (XMAD:LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued.
The current stock price of €6.40 is trading 77.3% above its estimated GF Value™ of €3.61.
GuruFocus considers Labiana Health to be Significantly Overvalued.
Key valuation signals for XMAD:LAB:
EV-to-Revenue: 1.13 (24% above median its 10-year median of 0.91)
GF Value™: €3.61 vs. price of €6.40 (77.3% above fair value)
Industry Position: 54.6% below the Drug Manufacturers median (#229 of 963)
No single metric tells the full story. See the XMAD:LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
56GF Score
Get the complete analysis for XMAD:LAB
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:LAB has been successfully added to your 
